Gracell Biotechnologies Inc - ESG Rating & Company Profile powered by AI
This Disclosure rating includes seventeen United Nations Sustainable Development Goals including: 'Affordable & Clean Energy', 'Industry, Innovation & Infrastructure' and 'Life below Water'. The webpage is a zero-cost ESG assessment for Gracell Biotechnologies Inc. Other corporations in the rating peer group for Gracell Biotechnologies Inc are shownin the table.
Gracell Biotechnologies Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.9; made up of an environmental score of 4.0, social score of 1.6 and governance score of 3.2.
2.9
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1336 | SyneuRx International (Taiwan) Corp | 3.0 | Medium |
1336 | Sensorion SA | 3.0 | Medium |
1353 | Gracell Biotechnologies Inc | 2.9 | Medium |
1353 | Caribou Biosciences Inc | 2.9 | Medium |
1353 | Checkmate Pharmaceuticals Inc | 2.9 | Medium |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Gracell Biotechnologies Inc have an accelerator or VC vehicle to help deliver innovation?
Does Gracell Biotechnologies Inc disclose current and historical energy intensity?
Does Gracell Biotechnologies Inc report the average age of the workforce?
Does Gracell Biotechnologies Inc reference operational or capital allocation in relation to climate change?
Does Gracell Biotechnologies Inc disclose its ethnicity pay gap?
Does Gracell Biotechnologies Inc disclose cybersecurity risks?
Does Gracell Biotechnologies Inc offer flexible work?
Does Gracell Biotechnologies Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Gracell Biotechnologies Inc disclose the number of employees in R&D functions?
Does Gracell Biotechnologies Inc conduct supply chain audits?
Does Gracell Biotechnologies Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Gracell Biotechnologies Inc conduct 360 degree staff reviews?
Does Gracell Biotechnologies Inc disclose the individual responsible for D&I?
Does Gracell Biotechnologies Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Gracell Biotechnologies Inc disclose current and / or historical scope 2 emissions?
Does Gracell Biotechnologies Inc disclose water use targets?
Does Gracell Biotechnologies Inc have careers partnerships with academic institutions?
Did Gracell Biotechnologies Inc have a product recall in the last two years?
Does Gracell Biotechnologies Inc disclose incidents of discrimination?
Does Gracell Biotechnologies Inc allow for Work Councils/Collective Agreements to be formed?
Has Gracell Biotechnologies Inc issued a profit warning in the past 24 months?
Does Gracell Biotechnologies Inc disclose parental leave metrics?
Does Gracell Biotechnologies Inc disclose climate scenario or pathway analysis?
Does Gracell Biotechnologies Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Gracell Biotechnologies Inc disclose the pay ratio of women to men?
Does Gracell Biotechnologies Inc support suppliers with sustainability related research and development?
Does Gracell Biotechnologies Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Gracell Biotechnologies Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Gracell Biotechnologies Inc involved in embryonic stem cell research?
Does Gracell Biotechnologies Inc disclose GHG and Air Emissions intensity?
Does Gracell Biotechnologies Inc disclose its waste policy?
Does Gracell Biotechnologies Inc report according to TCFD requirements?
Does Gracell Biotechnologies Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Gracell Biotechnologies Inc disclose energy use targets?
Does Gracell Biotechnologies Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Gracell Biotechnologies Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Gracell Biotechnologies Inc
These potential risks are based on the size, segment and geographies of the company.
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 1/2 registrational trial clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.